Schizophrenia Research
Volume 71, Issue 1 , Pages 97-101 , 1 November 2004

Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder

Received 15 August 2003 ,Revised 3 December 2003 ,Accepted 10 December 2003.

References 

  1. Baron M, Gruen R, Asnis L, Lord S. Familial transmission of schizotypal and borderline personality disorders. Am. J. Psychiatry. 1985;142:927–934
  2. Bymaster FP, Nelson DL, DeLapp NW, et al.  Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr. Res. 1999;37:107–122
  3. Cadenhead KS, Light GA, Geyer MA, McDowell JE, Braff DL. Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype?. Am. J. Psychiatry. 2002;159:869–871
  4. Fenton WS, McGlashan TH. Risk of schizophrenia in character disordered patients. Am. J. Psychiatry. 1989;146(10):1280–1284
  5. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr. Psychiatry. 1993;34:402–405
  6. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs. placebo. Arch. Gen. Psychiatry. 1986;43:680–686
  7. Gunderson JG, Phillips KA. Comprehensive Textbook of Psychiatry. Philadelphia: Williams and Wilkins; 1995;
  8. Jensen HV, Andersen J. An open, noncomparative study of amoxapine in borderline disorders. Acta Psychiatr. Scand. 1989;79:89–93
  9. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry. 2001;62:92–100
  10. Loranger AD, Jeffrey AL, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR. The personality disorder examination: a preliminary report. J. Psychiatr. Educ. 1987;1:1–13
  11. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry. 2002;59(10):921–928
  12. Park S, McTigue K. Working memory and the syndromes of schizotypal personality. Schizophr. Res. 1997;29(26(2-3)):213–220
  13. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol. Psychiatry. 1999;46:1429–1435
  14. Siever LJ, Keefe R, Bernstein DP, et al.  Eye tracking impairment in clinically identified patients with schizotypal personality disorder. Am. J. Psychiatry. 1990;147:740–745
  15. Siever LJ, Silverman JM, Horvath TB, et al.  Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients. Arch. Gen. Psychiatry. 1990;47:634–640
  16. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch. Gen. Psychiatry. 1986;43:691–697
  17. Soloff PH, George A, Nathan S, et al.  Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J. Clin. Psychopharmacol. 1989;9:238–246
  18. Stein G. Drug treatment of the personality disorders. Br. J. Psychiatry. 1992;161:167–184
  19. Tsuang MT, Stone WS, Seidman LJ, Faraone SV, Zimmet S, Wojcik J, et al. Treatment of non-psychotic relatives of patients with schizophrenia: four case studies. Biol. Psychiatry. 1999;45(11):1412–1418

PII: S0920-9964(04)00010-6

doi: 10.1016/j.schres.2003.12.008

Schizophrenia Research
Volume 71, Issue 1 , Pages 97-101 , 1 November 2004

Article Tools